{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"}]}],"title":"Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"13"}]}],"title":"TEAEs Related to Study Drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]}],"title":"Any serious TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Serious TEAEs Related to Study Drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"}]}],"title":"TEAEs with Severity Grade 3 or Higher"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"title":"TEAEs Related to Study Drug with Severity Grade 3 or Higher"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"TEAEs Leading to Death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"TEAEs Related to Study Drug Leading to Death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"TEAEs Leading to Study Drug Discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"TEAEs Related to Study Drug Leading to Study Drug Discontinuation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. An AE is considered to be treatment-emergent if it has a start date/time on or after the first administration of study drug until 30 days after the last dose of study drug and before the start of subsequent therapy, whichever comes earlier. The distribution of AEs was analyzed by the type, frequency and severity for TEAEs.","groups":[{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).","id":"OG000","title":"Melanoma Cohort"},{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.","id":"OG001","title":"Tissue Agnostic Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set comprises of all patients enrolled in the study who receive at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to 23 months","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}